Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 37

Results For "2025"

715 News Found

Shin-Etsu Chemical to invest in pharmaceutical cellulose business
News | April 01, 2025

Shin-Etsu Chemical to invest in pharmaceutical cellulose business

L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets


GE HealthCare launches new advanced CT system
News | April 01, 2025

GE HealthCare launches new advanced CT system

GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology


Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
News | April 01, 2025

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur


OneSource Specialty Pharma updates on cGMP inspection by USFDA
Drug Approval | April 01, 2025

OneSource Specialty Pharma updates on cGMP inspection by USFDA

The inspection has concluded with four observations


DKSH Technology acquires Korean life science firm MDxK
Supply Chain | March 31, 2025

DKSH Technology acquires Korean life science firm MDxK

The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market


Merck seeks FDA approval for subcutaneous pembrolizumab
Drug Approval | March 29, 2025

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy


European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
Drug Approval | March 27, 2025

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults


Merck inks $200 million deal for Hengrui's midstage heart disease drug
News | March 26, 2025

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region


Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda
Healthcare | March 25, 2025

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda

Nadda noted that TB treatment coverage in India has increased from 59% to 85%


Briefs: Alembic Pharmaceuticals and Shelter Pharma
News | March 24, 2025

Briefs: Alembic Pharmaceuticals and Shelter Pharma

Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility